X
VRTX icon

Xponance’s Vertex Pharmaceuticals VRTX Stock Holding History

Xponance’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.8M Sell
45,980
-24,734
-35% -$11M 0.14% 109
2026
Q1 		$31.6M Buy
70,714
+4,941
+8% +$2.3M 0.22% 73
2025
Q4 		$29.8M Buy
65,773
+3,282
+5% +$1.41M 0.22% 73
2025
Q3 		$24.5M Sell
62,491
-109
-0.2% -$45.6K 0.19% 81
2025
Q2 		$27.9M Buy
62,600
+13,431
+27% +$6.19M 0.23% 68
2025
Q1 		$23.8M Buy
49,169
+662
+1% +$308K 0.23% 71
2024
Q4 		$19.5M Buy
48,507
+539
+1% +$250K 0.18% 88
2024
Q3 		$22.3M Buy
47,968
+273
+0.6% +$131K 0.22% 75
2024
Q2 		$22.4M Sell
47,695
-11,371
-19% -$4.94M 0.23% 67
2024
Q1 		$24.7M Buy
59,066
+413
+0.7% +$175K 0.26% 62
2023
Q4 		$23.9M Buy
58,653
+562
+1% +$208K 0.29% 61
2023
Q3 		$20.2M Buy
58,091
+689
+1% +$241K 0.27% 61
2023
Q2 		$20.2M Sell
57,402
-69
-0.1% -$23.2K 0.27% 63
2023
Q1 		$18.1M Buy
57,471
+1,331
+2% +$399K 0.26% 69
2022
Q4 		$16.2M Buy
56,140
+4,870
+9% +$1.48M 0.26% 75
2022
Q3 		$14.8M Buy
51,270
+3,772
+8% +$1.09M 0.29% 63
2022
Q2 		$13.4M Buy
47,498
+20,198
+74% +$5.41M 0.27% 68
2022
Q1 		$7.12M Buy
27,300
+533
+2% +$126K 0.12% 147
2021
Q4 		$5.88M Buy
26,767
+3,078
+13% +$599K 0.09% 189
2021
Q3 		$4.3M Sell
23,689
-1,226
-5% -$239K 0.08% 201
2021
Q2 		$5.02M Sell
24,915
-13,243
-35% -$2.77M 0.09% 180
2021
Q1 		$8.2M Sell
38,158
-93
-0.2% -$20.4K 0.17% 111
2020
Q4 		$9.04M Buy
38,251
+836
+2% +$192K 0.2% 91
2020
Q3 		$10.2M Buy
37,415
+22
+0.1% +$6.07K 0.25% 75
2020
Q2 		$10.9M Buy
+37,393
New +$10.1M 0.28% 69

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Xponance's VRTX Position: Q2 2026 in Review

Xponance reduced its Vertex Pharmaceuticals (VRTX) stake by 35% in Q2 2026, selling an estimated $11M and leaving 45,980 shares worth $22.8M. The position accounts for 0.14% of the portfolio, ranked #109.

Xponance first reported a position in VRTX in Q2 2020 and has held it in 25 quarters since. The position peaked at $31.6M in Q1 2026. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Xponance held 45,980 shares of Vertex Pharmaceuticals worth $22.8M as of Q2 2026.
  • Xponance sold 24,734 Vertex Pharmaceuticals shares in Q2 2026, an estimated $11M.
  • Vertex Pharmaceuticals made up 0.14% of Xponance's portfolio in Q2 2026, its #109 holding.
  • Xponance first reported a position in Vertex Pharmaceuticals in Q2 2020 and has held it in 25 quarters since.
  • Xponance's Vertex Pharmaceuticals position peaked at $31.6M in Q1 2026.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.